Upstream Bio, Inc. (UPB)
UPBNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$3.38
-0.2000 (-5.59%) today
At the close, Nov 10, 4:00 PM ET. After hours $3.38 –
- Market cap
- $185.13m
- P/E
- –
- EPS, last 4 quarters
- $-2.90
- Dividend yield
- –
- Day range
- $3.24 to $3.65
- 52-week range
- $2.68 to $33.68
- Average volume
- 980.1k
- Previous close
- $3.58
Analysts
6 coveringBuy4 buy, 2 hold, 0 sell
Targets a year out average $22.25, +558.3% from here
Earnings
next estimate $-0.6700Next report Nov 11, 2026
Sep 2025
+19.2%
Dec 2025
-8.2%
Mar 2026
+6.3%
Jun 2026
+6.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $683.0k | $668.0k | $1.03m | $773.0k |
| Gross profit | $683.0k | $668.0k | $1.03m | $773.0k |
| Operating income | -$37.83m | -$46.17m | -$43.62m | -$42.37m |
| Net income | -$33.75m | -$42.46m | -$40.59m | -$39.70m |
Last four quarters: revenue $3.16m, margin -4955.7%, free cash flow –
News
8 latest- Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue EstimatesZacks · 10 hours ago
- Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 2, 2026
- Upstream Posts Narrower Loss In Q2; Expects Phase 2 Readouts For Verekitug In H2 2027 RTTNews · Aug 13, 2026
- Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue EstimatesZacks · Aug 11, 2026
- Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Jul 14, 2026
- Upstream Bio Presents Clinically Meaningful Improvements In Phase 2 VIBRANT Trial On Verekitug RTTNews · Jun 15, 2026
- Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue EstimatesZacks · May 13, 2026
- Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue EstimatesZacks · Apr 30, 2026
The company
Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple inflammatory pathways. With more than 500 participants treated with verekitug across its clinical development programs and positive Phase 2 results in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, verekitug has a substantial body of clinical evidence supporting its advancement into Phase 3 development in both diseases. Verekitug is also being evaluated in an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- upstreambio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.